JP2005504783A - イロペリドン代謝産物の光学異性体 - Google Patents

イロペリドン代謝産物の光学異性体 Download PDF

Info

Publication number
JP2005504783A
JP2005504783A JP2003524978A JP2003524978A JP2005504783A JP 2005504783 A JP2005504783 A JP 2005504783A JP 2003524978 A JP2003524978 A JP 2003524978A JP 2003524978 A JP2003524978 A JP 2003524978A JP 2005504783 A JP2005504783 A JP 2005504783A
Authority
JP
Japan
Prior art keywords
acid addition
free base
addition salt
pharmaceutically acceptable
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2003524978A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005504783A5 (enExample
Inventor
ドミニク・グリムレ
ハンス・オー・カルクマン
イン・ヘクン
Original Assignee
ノバルティス アクチエンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アクチエンゲゼルシャフト filed Critical ノバルティス アクチエンゲゼルシャフト
Publication of JP2005504783A publication Critical patent/JP2005504783A/ja
Publication of JP2005504783A5 publication Critical patent/JP2005504783A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicinal Preparation (AREA)
JP2003524978A 2001-08-31 2002-08-30 イロペリドン代謝産物の光学異性体 Withdrawn JP2005504783A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31639001P 2001-08-31 2001-08-31
PCT/EP2002/009700 WO2003020707A1 (en) 2001-08-31 2002-08-30 Optical isomers of an iloperidone metabolite

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009281094A Division JP2010100633A (ja) 2001-08-31 2009-12-11 イロペリドン代謝産物の光学異性体

Publications (2)

Publication Number Publication Date
JP2005504783A true JP2005504783A (ja) 2005-02-17
JP2005504783A5 JP2005504783A5 (enExample) 2009-08-27

Family

ID=23228843

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2003524978A Withdrawn JP2005504783A (ja) 2001-08-31 2002-08-30 イロペリドン代謝産物の光学異性体
JP2009281094A Withdrawn JP2010100633A (ja) 2001-08-31 2009-12-11 イロペリドン代謝産物の光学異性体
JP2013017050A Withdrawn JP2013116905A (ja) 2001-08-31 2013-01-31 イロペリドン代謝産物の光学異性体
JP2013142873A Pending JP2013227335A (ja) 2001-08-31 2013-07-08 イロペリドン代謝産物の光学異性体
JP2015156358A Pending JP2015227368A (ja) 2001-08-31 2015-08-06 イロペリドン代謝産物の光学異性体
JP2015156359A Pending JP2015214577A (ja) 2001-08-31 2015-08-06 イロペリドン代謝産物の光学異性体

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2009281094A Withdrawn JP2010100633A (ja) 2001-08-31 2009-12-11 イロペリドン代謝産物の光学異性体
JP2013017050A Withdrawn JP2013116905A (ja) 2001-08-31 2013-01-31 イロペリドン代謝産物の光学異性体
JP2013142873A Pending JP2013227335A (ja) 2001-08-31 2013-07-08 イロペリドン代謝産物の光学異性体
JP2015156358A Pending JP2015227368A (ja) 2001-08-31 2015-08-06 イロペリドン代謝産物の光学異性体
JP2015156359A Pending JP2015214577A (ja) 2001-08-31 2015-08-06 イロペリドン代謝産物の光学異性体

Country Status (9)

Country Link
US (4) US20050020632A1 (enExample)
EP (2) EP2305656B1 (enExample)
JP (6) JP2005504783A (enExample)
AT (1) ATE518845T1 (enExample)
CY (2) CY1112039T1 (enExample)
DK (2) DK2305656T3 (enExample)
ES (2) ES2398434T3 (enExample)
PT (2) PT2305656E (enExample)
WO (1) WO2003020707A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506481A (ja) * 2007-12-13 2011-03-03 ヴァンダ ファーマシューティカルズ インコーポレイテッド αアドレナリン受容体介在状態を治療する方法及び組成物
JP2015510893A (ja) * 2012-03-14 2015-04-13 ヴァンダ ファーマシューティカルズ インコーポレイテッド 精神障害の治療における使用のためのイロペリドン代謝物

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2358416T3 (es) 2001-10-30 2011-05-10 Novartis Ag Formulaciones de liberación prolongada de iloperidona y polímero en forma de estrella.
SI1497266T1 (sl) 2002-03-27 2008-10-31 Glaxo Group Ltd Derivati kinolina in njihova uporaba kot ligandi 5-ht6
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
EP1558582B1 (en) 2003-07-22 2005-12-21 Arena Pharmaceuticals, Inc. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of disorders related thereto
GB0322994D0 (en) * 2003-10-01 2003-11-05 Novartis Ag Organic compounds
EP1799865B1 (en) 2004-09-30 2012-06-06 Vanda Pharmaceuticals Inc. Methods for the administration of iloperidone
US20100063093A1 (en) 2007-03-28 2010-03-11 Curt Wolfgang Methods for the administration of iloperidone
US20070262395A1 (en) 2006-05-11 2007-11-15 Gibbons Jasper S Memory cell access devices and methods of making the same
US8008144B2 (en) 2006-05-11 2011-08-30 Micron Technology, Inc. Dual work function recessed access device and methods of forming
US20090306137A1 (en) 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
WO2008121899A2 (en) 2007-03-29 2008-10-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
US20150259747A1 (en) 2007-03-29 2015-09-17 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation
WO2008128166A1 (en) * 2007-04-13 2008-10-23 Concert Pharmaceuticals Inc. Deuterated derivatives of 4-(6-fluoro-1, 2-benzisoxazol-3-yl) piperidine compounds
EP3075865B1 (en) 2007-05-18 2018-05-09 Vanda Pharmaceuticals Inc. Genetic markers for efficacy of iloperidone in the treatment of psychotic symptoms
US8652776B2 (en) 2007-09-10 2014-02-18 Vanda Pharmaceuticals, Inc. Prediction of QT prolongation based on SNP genotype
EP2254564A1 (en) 2007-12-12 2010-12-01 Glaxo Group Limited Combinations comprising 3-phenylsulfonyl-8-piperazinyl-1yl-quinoline
CA2709104C (en) 2007-12-13 2017-06-13 Vanda Pharmaceuticals Inc. Method and composition for treating a serotonin receptor-mediated condition
US20110061014A1 (en) 2008-02-01 2011-03-10 Energyhub Interfacing to resource consumption management devices
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010062321A1 (en) 2008-10-28 2010-06-03 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2h-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)-urea and crystalline forms related thereto
US7824986B2 (en) 2008-11-05 2010-11-02 Micron Technology, Inc. Methods of forming a plurality of transistor gates, and methods of forming a plurality of transistor gates having at least two different work functions
JP5881597B2 (ja) 2009-04-06 2016-03-09 ヴァンダ ファーマシューティカルズ インコーポレイテッド Ｑｔ延長に対する素因を予測する方法
EP2416779B1 (en) 2009-04-06 2016-03-09 Vanda Pharmaceuticals Inc. Method of predicting a predisposition to qt prolongation based on bai3 gene sequence or product thereof
ES2604102T3 (es) 2009-04-06 2017-03-03 Vanda Pharmaceuticals Inc. Método de tratamiento basado en polimorfismos del gen KCNQ1
WO2010117941A1 (en) 2009-04-06 2010-10-14 Vanda Pharmaceuticals, Inc. Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof
BR112012015084A2 (pt) 2009-12-23 2017-03-07 Lupin Ltd composição farmacêutica de liberação lenta de iloperidone
US9000221B2 (en) 2010-09-07 2015-04-07 Symed Labs Limited Processes for the preparation of 4′-[3-[4-(6-Fluoro-1 ,2-benzisoxazol-3-yl)piperidino]propoxy]-3′-methoxyacetophenone and intermediates thereof
WO2012063269A2 (en) 2010-11-12 2012-05-18 Cadila Healthcare Limited Process for preparing iloperidone
CA2976383C (en) 2015-02-17 2023-05-23 Vanda Pharmaceuticals Inc. Iloperidone for the treatment of schizophrenia
HK1245660A1 (zh) 2015-06-12 2018-08-31 Axovant Sciences Gmbh 有用於预防和治疗rem睡眠行为障碍的二芳基脲和芳基脲衍生物
WO2017011767A2 (en) 2015-07-15 2017-01-19 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives as modulators of the 5-ht2a serotonin receptor useful for the prophylaxis and treatment of hallucinations associated with a neurodegenerative disease
CN114941015B (zh) * 2019-02-21 2024-05-03 深圳艾欣达伟医药科技有限公司 制造高镜像选择性二级醇的方法
US11607408B2 (en) 2019-10-15 2023-03-21 Vanda Pharmaceuticals Inc. Method of treatment of schizophrenia
WO2023201182A1 (en) 2022-04-13 2023-10-19 Vanda Pharmaceuticals Inc. Treatment of parkinson's disease and parkinson's disease psychosis
WO2024137439A1 (en) 2022-12-19 2024-06-27 Vanda Pharmaceuticals Inc. Dosage regime of iloperidone for treating bipolar i disorder and schizophrenia
KR20260019503A (ko) 2023-06-02 2026-02-10 반다 파마슈티칼즈, 인코퍼레이티드. 일로페리돈을 사용한 치료 방법

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
US5158952A (en) * 1988-11-07 1992-10-27 Janssen Pharmaceutica N.V. 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use
US5364866A (en) * 1989-05-19 1994-11-15 Hoechst-Roussel Pharmaceuticals, Inc. Heteroarylpiperidines, pyrrolidines and piperazines and their use as antipsychotics and analetics
US5776963A (en) 1989-05-19 1998-07-07 Hoechst Marion Roussel, Inc. 3-(heteroaryl)-1- (2,3-dihydro-1h-isoindol-2-yl)alkyl!pyrrolidines and 3-(heteroaryl)-1- (2,3-dihydro-1h-indol-1-yl)alkyl!pyrrolidines and related compounds and their therapeutic untility
ES2076253T3 (es) * 1989-05-19 1995-11-01 Hoechst Roussel Pharma N-(ariloxialquil)-heteroarilpiperidinas y -heteroarilpiperazinas, un procedimiento para su preparacion y su uso como medicamentos.
JPH05286868A (ja) 1992-04-03 1993-11-02 Kiyoshi Okawa 制がん剤複合体およびそのスクリーニング法
US5889006A (en) * 1995-02-23 1999-03-30 Schering Corporation Muscarinic antagonists
US6172099B1 (en) * 1997-07-03 2001-01-09 Asahi Kasei Kogyo Kabushiki Kaisha Tricyclic compounds having saturated rings and medicinal compositions containing the same
EP1551393A4 (en) 2002-07-30 2010-06-16 Peter Migaly COMBINATION OF THERAPY FOR DEPRESSION, PREVENTION OF SUICIDE AND VARIOUS MEDICAL AND PSYCHIATRIC DISORDERS

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011506481A (ja) * 2007-12-13 2011-03-03 ヴァンダ ファーマシューティカルズ インコーポレイテッド αアドレナリン受容体介在状態を治療する方法及び組成物
JP2015510893A (ja) * 2012-03-14 2015-04-13 ヴァンダ ファーマシューティカルズ インコーポレイテッド 精神障害の治療における使用のためのイロペリドン代謝物
JP2017061506A (ja) * 2012-03-14 2017-03-30 ヴァンダ ファーマシューティカルズ インコーポレイテッド 精神障害の治療における使用のためのイロペリドン代謝物
JP2018203774A (ja) * 2012-03-14 2018-12-27 ヴァンダ ファーマシューティカルズ インコーポレイテッド 精神障害の治療における使用のためのイロペリドン代謝物
US10874659B2 (en) 2012-03-14 2020-12-29 Vanda Pharmaceuticals Inc. Iloperidone metabolite for use in the treatment of psychiatric disorders
JP2021001221A (ja) * 2012-03-14 2021-01-07 ヴァンダ ファーマシューティカルズ インコーポレイテッド 精神障害の治療における使用のためのイロペリドン代謝物
JP7151029B2 (ja) 2012-03-14 2022-10-12 ヴァンダ ファーマシューティカルズ インコーポレイテッド 精神障害の治療における使用のためのイロペリドン代謝物
JP2023022243A (ja) * 2012-03-14 2023-02-14 ヴァンダ ファーマシューティカルズ インコーポレイテッド 精神障害の治療における使用のためのイロペリドン代謝物

Also Published As

Publication number Publication date
US8314129B2 (en) 2012-11-20
DK2305656T3 (da) 2013-02-11
HK1156309A1 (en) 2012-09-07
WO2003020707A1 (en) 2003-03-13
ES2398434T8 (es) 2017-10-09
JP2013116905A (ja) 2013-06-13
HK1066536A1 (en) 2005-03-24
PT2305656E (pt) 2013-01-10
US20110201646A1 (en) 2011-08-18
EP2305656B1 (en) 2012-10-24
DK1425272T3 (da) 2011-11-21
CY1112039T1 (el) 2015-11-04
ES2370634T3 (es) 2011-12-21
JP2015227368A (ja) 2015-12-17
ES2398434T3 (es) 2013-03-19
EP2305656A1 (en) 2011-04-06
US20130296366A1 (en) 2013-11-07
ATE518845T1 (de) 2011-08-15
CY1113550T1 (el) 2016-06-22
US7977356B2 (en) 2011-07-12
JP2015214577A (ja) 2015-12-03
US20050020632A1 (en) 2005-01-27
US20090176739A1 (en) 2009-07-09
JP2013227335A (ja) 2013-11-07
JP2010100633A (ja) 2010-05-06
EP1425272A1 (en) 2004-06-09
EP1425272B1 (en) 2011-08-03
PT1425272E (pt) 2011-10-19

Similar Documents

Publication Publication Date Title
JP2013227335A (ja) イロペリドン代謝産物の光学異性体
CN1123571C (zh) 用作nmda受体拮抗剂的1－(3－杂芳基丙基－或－丙－2－烯基)－4－苄基哌啶
CA2128380C (en) 4-aryloxy- and 4-arylthiopiperidine derivatives
WO2014001282A1 (en) A phenyl triazole derivative and its use for modulating the gabaa receptor complex
KR20000075697A (ko) 5-ｈｔ2ａ-길항제로서의 옥사졸리딘
US20200131166A1 (en) Benzisoxazoles
JP2005527500A (ja) ５ｈｔ１−型受容体でのアフィニティーを有するヘテロサイクリック化合物および治療におけるその使用
EA011636B1 (ru) Производные амида кинуреновой кислоты как антагонисты nr2b подтипа рецептора nmda
JPH10509713A (ja) α−１Ｃアドレナリン作動性レセプターのアンタゴニストとしてのオキサゾール誘導体
JPH09508404A (ja) フェニルピロール誘導体およびそのドーパミンｄ▲下３▼アンタゴニストとしての使用
HK1156309B (en) Optical isomers of an iloperidone metabolite
HK1066536B (en) Optical isomers of an iloperidone metabolite
JPH09508917A (ja) フェニルピロール誘導体およびそのドーパミンｄ▲下３▼アンタゴニストとしての使用
JP2005529073A (ja) ５ｈｔ−１型受容体でアフィニティーを有するヘテロサイクリルメチルピペリジンおよび−ピペラジン
HK1093729B (en) Benzisoxazoles
HK1093729A1 (en) Benzisoxazoles

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050615

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090210

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090511

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090518

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090610

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090617

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20090710

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090811

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100201